EUVIMEDEUVIMED entdecken
Studienprotokoll

The Bioefficacy Protocol: biomarkers identification of TNF inhibitors efficacy in axial spondyloarthritis patients using transcriptome and proteome analysis

Rita Pinheiro Torres, Ana Filipa Fernandes, Sara Maia, Jaime Cunha Branco, Daniel Sobral, Ana Varela Coelho, Fernando Pimentel-Santos

ARP Rheumatology · 2024

DOI: 10.63032/prej7967 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift ARP Rheumatology, 2024. Verfasst von Rita Pinheiro Torres und 6 weiteren Autor:innen. Beteiligte Einrichtung: ULS Cova da Beira. Hauptthemen laut MEDLINE: Adalimumab, Axial Spondyloarthritis, Biomarkers, Proteome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Axial Spondyloarthritis (axSpA) is a chronic inflammatory rheumatic condition affecting the axial skeleton, leading to pain, stiffness, and fatigue. While biologic therapies have improved clinical management, many patients experience partial or no responses, resulting in delays in disease control. Additionally, the risk of adverse events and increased costs remains a concern. OBJECTIVES: Our primary objectives are: 1. to identify reliable markers for treatment response to Tumor Necrosis Factor alpha inhibitors (TNFi), in particular Adalimumab, enabling the identification of individuals most likely to benefit; 2. to analyze the impact of TNFi on gene and protein expression. METHODS: A multicenter, prospective 14-week study will be conducted with 36 participants aged 18-75 years, meeting the ASAS criteria for axSpA. Patient enrollment will follow the National Guidelines for the use of TNFi in axSpA treatment, with all included patients using TNFi (Adalimumab) as a first-line option. Epidemiological and clinical data will be collected, along with peripheral blood samples, for integrated transcriptome, using RNA Seq (whole genome sequencing) and proteome analysis at various time points (baseline, 3-5 days, weeks 2 and 14), corresponding to the initial administration of TNFi. Patients will be classified as responders and non-responders, primarily based on ASAS20 criteria and secondarily based on ASDAS-C Reactive Protein (CRP), at week 14. DISCUSSION: This project's innovative approach lies in identifying potential biomarkers for TNFi (Adalimumab) response at baseline, paving the way for advancements in precision medicine in this field. Additionally, it seeks to establish evidence of the therapy's impact on gene and protein expression, offering deeper insights into the pathophysiological mechanisms underlying the therapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabAxial SpondyloarthritisBiomarkersProteomeTranscriptomeTumor Necrosis Factor InhibitorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAntirheumatic AgentsProspective StudiesProteomicsTreatment OutcomeClinical Trials as TopicMulticenter Studies as Topic

Substanzen

AdalimumabAntirheumatic AgentsBiomarkersProteomeTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • ULS Cova da Beira.
  • Instituto de Tecnologia Química e Biológica António Xavier.
  • Universidade NOVA de Lisboa, Lisboa.
  • ULS de Lisboa Ocidental.
  • National Institute of Health Doutor Ricardo Jorge (INSA).
  • Hospital Egas Moniz - Centro Hospitalar Lisboa Ocidental.

Zitieren

APA

Torres, R. P., Fernandes, A. F., Maia, S., Branco, J. C., Sobral, D., Coelho, A. V., & Pimentel-Santos, F. (2024). The Bioefficacy Protocol: biomarkers identification of TNF inhibitors efficacy in axial spondyloarthritis patients using transcriptome and proteome analysis. ARP Rheumatology. https://doi.org/10.63032/prej7967

Vancouver

Torres RP, Fernandes AF, Maia S, Branco JC, Sobral D, Coelho AV, et al. The Bioefficacy Protocol: biomarkers identification of TNF inhibitors efficacy in axial spondyloarthritis patients using transcriptome and proteome analysis. ARP Rheumatology. 2024. doi:10.63032/prej7967

BibTeX
@article{Torres2024,
  author = {Torres, Rita Pinheiro and Fernandes, Ana Filipa and Maia, Sara and Branco, Jaime Cunha and Sobral, Daniel and Coelho, Ana Varela and Pimentel-Santos, Fernando},
  title = {The Bioefficacy Protocol: biomarkers identification of TNF inhibitors efficacy in axial spondyloarthritis patients using transcriptome and proteome analysis},
  journal = {ARP Rheumatology},
  year = {2024},
  doi = {10.63032/prej7967}
}
Kostenlos starten →